Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Cervical Cytology and Herpes Simplex Virus Type-2 Serology Among Human Immune Deficiency Virus Infected Women on Highly Active Antiretroviral Therapy in Enugu, Nigeria

Author(s): Cornelius Osinachi Ogu*, Peter Uwadiegwu Achukwu, Peter Onubiwe Nkwo, Rita Ifeoma-Ossy Ogu, Okechukwu Steven Onwukwe, Nkiruka Chinonye Azubuike, Anulika Obianuju Onyemelukwe, Ijeoma Maryjoy Ifeorah and Maduakor Charity Uzoamaka

Volume 20, Issue 6, 2022

Published on: 21 November, 2022

Page: [463 - 471] Pages: 9

DOI: 10.2174/1570162X21666221114102411

Price: $65

Abstract

Background: The prevalence of Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus type-2 (HSV-2) infections are high and the programme for Cervical Cancer Screening is weak in Nigeria.

Objectives: Prevalence of Herpes Simplex Virus Type-2 co-infection and cervical cytology among HSV-2 co-infected Human Immunodeficiency Virus Sero-positive (HIV+) women on Highly Active Antiretroviral Therapy (HAART) attending Human Immunodeficiency Virus clinic at University of Nigeria Teaching Hospital (UNTH) Ituku/Ozalla Enugu, Nigeria.

Methods: A cross-sectional, hospital-based study. Active participants included 105 HIV seropositive women on HAART and104 HIV seronegative (HIV-) women who passed inclusion criteria and signed written informed consent. Each participant was coded with a specific number. A structured questionnaire was used to obtain the socio-demographic and medical history. Serum was obtained for HSV-2 serology test for all participants and HIV screening for HIV-negative participants. Cervical smears were collected for Papanicolaou stains and Immunocytochemistry using anti-P16INKa antibody.

Results: Prevalence of HSV-2+ was 50.5% among HIV+ women on HAART and 16.3% among HIV- women, Odds Ratios [95% CI]; p-value was 5.21 [2.74-9.94]; p < 0.0001. HIV+ women on HAART co-infected with HSV-2 significantly had more Cervical Lesions, 11.4% compared to HIVwomen uninfected with HSV-2, 4.8%, OR [95% CI]; p-value 4.8 (1.58-14.54); p = 0.006.

Conclusion: The prevalence of HSV-2 was significantly high among HIV+ women on HAART. HSV-2+ co-infection could be an enhancer of Cervical Lesions among HIV+ women on HAART. Hence, anti-herpetic agent introduction and screening for HSV-2 among HIV+ patients are recommended.

« Previous Next »
Graphical Abstract

[1]
National Agency for the Control of AIDS Nigeria. Nigeria prevalence rate, National HIV and AIDS strategic framework 2019. Available from: http://naca.gov (Accessed on: 8th March 2020).
[2]
UNSAIDS. Unaidsinfo 2019. Available from: https://wwwunaids.org/en/resources/presscentre/pressreleaseandstatementarcive/2019/march/20190314_nigeria (Accessed on: 5th July 2020).
[3]
UNICEF. At a glance, Nigeria-Statistics 2010. Available from: www.unicef.org/infobycountry/nigeria_statistics.html#66 (Accessed on: 12th July, 2018).
[4]
Media centre. cancer facts sheets 2012. Available from: http://www.who.int/medicalcentre/factsheets/fs297/en/ (Accessed on: 10th June, 2016).
[5]
Dim CC, Nwagha UI, Ezegwui HU, Dim NR. The need to incorporate routine cervical cancer counselling and screening in the management of women at the outpatient clinics in Nigeria. J Obstet Gynaecol 2009; 29(8): 754-6.
[http://dx.doi.org/10.3109/01443610903225323] [PMID: 19821672]
[6]
U.S. Preventive Services Task Force. Screening for cervical cancer control. 2012. Available from: http/www.uspreventiveservicestaskforce.org/usps (accessed on: 3rd May, 2016).
[7]
Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101(16): 1120-30.
[http://dx.doi.org/10.1093/jnci/djp205] [PMID: 19648510]
[8]
Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Mortality Morbidity Weekly Report. Recommendation Report 1992; 41(RR-17): 1-19.
[9]
Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 2015; 10(1): e114989.
[http://dx.doi.org/10.1371/journal.pone.0114989] [PMID: 25608026]
[10]
Des Jarlais DC, Hagan H, Arasteh K, McKnight C, Perlman D, Friedman SR. Herpes simplex virus-2 and HIV among noninjecting drug users in New York city. Sex Transm Dis 2007; 34(11): 923-7.
[http://dx.doi.org/10.1097/OLQ.0b013e3180ca9647] [PMID: 18049425]
[11]
Hagan H, Jenness SM, Wendel T, Murrill CR, Neaigus A, Gelpi-Acosta C. Herpes simplex virus type 2 associated with HIV infection among New York heterosexuals living in high-risk areas. Int J STD AIDS 2010; 21(8): 580-3.
[http://dx.doi.org/10.1258/ijsa.2010.010137] [PMID: 20975092]
[12]
Patel P, Bush T, Mayer KH, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis 2012; 39(2): 154-60.
[http://dx.doi.org/10.1097/OLQ.0b013e318239d7fd] [PMID: 22249305]
[13]
Corey L, Langenberg AGM, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999; 282(4): 331-40.
[http://dx.doi.org/10.1001/jama.282.4.331] [PMID: 10432030]
[14]
Brown EL, Wald A, Hughes JP, et al. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol 2006; 164(8): 733-41.
[http://dx.doi.org/10.1093/aje/kwj270] [PMID: 16896053]
[15]
Barnabas RV, Wasserheit JN, Huang Y, et al. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 2011; 57(3): 238-44.
[http://dx.doi.org/10.1097/QAI.0b013e31821acb5] [PMID: 21860356]
[16]
Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immu-nodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008; 198(2): 241-9.
[http://dx.doi.org/10.1086/589621] [PMID: 18593294]
[17]
Sheth PM, Sunderji S, Shin LYY, et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis 2008; 197(10): 1394-401.
[http://dx.doi.org/10.1086/587697] [PMID: 18444797]
[18]
Roxby AC, Drake AL, John-Stewart G, et al. Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women. PLoS One 2011; 6(5): e19947.
[http://dx.doi.org/10.1371/journal.pone.0019947] [PMID: 21637835]
[19]
Tan DHS, Raboud JM, Kaul R, Walmsley SL. Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: An observational cohort study. BMJ Open 2014; 4(1): e004210.
[http://dx.doi.org/10.1136/bmjopen-2013-004210] [PMID: 24464523]
[20]
Ojinmah UR, Nnoruka EN, Ozoh GA, Onyekonwu CL, Aguwa EN. Herpes simplex virus type 2 infection among females in Enugu, Enugu State. Niger J Med 2012; 21(4): 394-403.
[PMID: 23304946]
[21]
Anaedobe C, Ajani T. Co-infection of herpes simplex virus Type 2 and HIV infections among pregnant women in Ibadan, Nigeria. J Glob Infect Dis 2019; 11(1): 19-24.
[http://dx.doi.org/10.4103/jgid.jgid_56_18] [PMID: 30814831]
[22]
Drisu UI, Oronsaye FE, Adejumo BIG, et al. Seroprevalence, type-specific of herpes simplex virus and associated risk factors among women of child bearing age in kogi state, Nigeria. Health (Irvine Calif) 2018; 10(7): 1006-17.
[http://dx.doi.org/10.4236/health.2018.107075]
[23]
Kalu EI. Seroprevalence of herpes simplex virus infections among pregnant women attending antenatal clinic in Benin, Nigeria. Int J Trop Dis Health 2013; 4: 70-81.
[24]
Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: Epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20(7): 1051-8.
[http://dx.doi.org/10.1097/01.aids.0000222078.75867.77] [PMID: 16603858]
[25]
Federal Ministry of Health (Nigeria). National survey on HIV/AIDS and reproductive health survey Federal Ministry of Health, Abuja, Nigeria 2006. Available from: https://books.google.com.ng/books/about/National_HIV_AIDS_Reproductive_Health_Su.html?id=hxcgAQAAIAAJ&redir_esc=y (Accessed on: 7th June, 2016).
[26]
Clinical Trials: A practical Approach Power calculator for binary outcome superiority trial 2012. Available from: http://www. sealedenvelope.com/power/binary-superiority/ (Accessed on: 22nd February 2017).
[27]
Chukwuali LI, Onuigbo WIB, Mgbor NC. A ten year descriptive analysis of women availing themselves of the cervical cancer screening service at medical women center, Enugu South Eastern Nigeria. Trop J Obstet Gynaecol 2003; 20(2): 109-12.
[28]
Ononogbu U, Almujtaba M, Modibbo F, et al. Cervical cancer risk factors among HIV-infected Nigerian women. BMC Public Health 2013; 13(1): 582.
[http://dx.doi.org/10.1186/1471-2458-13-582] [PMID: 23767681]
[29]
Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: A randomized, crossover trial. J Infect Dis 2011; 204(12): 1912-7.
[http://dx.doi.org/10.1093/infdis/jir649] [PMID: 21998479]
[30]
Ganesan A, Fieberg A, Agan BK, et al. Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care. Sex Transm Dis 2012; 39(6): 440-8.
[http://dx.doi.org/10.1097/OLQ.0b013e318249d90f] [PMID: 22592829]
[31]
Chow EPF, Wilson DP, Zhang L. HIV and syphilis co-infection increasing among men who have sex with men in China: A systematic review and meta-analysis. PLoS One 2011; 6(8): e22768.
[http://dx.doi.org/10.1371/journal.pone.0022768] [PMID: 21857952]
[32]
Clure C, Rivard C. Primary Herpes Simplex infection mimicking a cervical malignancy in an immunocompetent individual. Cureus 2018; 10(6): e2753.
[http://dx.doi.org/10.7759/cureus.2753] [PMID: 30094110]
[33]
CIPHER. The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Med 2018; 15(3): e1002514.
[34]
Data UNICEF. Statistical Update 2017. Available from: https://data. unicef.org/topic/hivaids/protection-care-and-support-for-children-affected-by-hiv-and-aids/ (Accessed on: 8th March 2020).
[35]
Cortés AJ. On how role versatility boosts an STI. J Theor Biol 2018; 440: 66-9.
[http://dx.doi.org/10.1016/j.jtbi.2017.12.018] [PMID: 29273545]
[36]
National Bureau of Statistics (NBS) and United Nations Children’s. Fund (UNICEF) Multiple Indicator Cluster Survey 2016-17, Survey Findings Report 2017. Available from: https://www.unicef. org/nigeria/NG_publication_mics_201617.pdf (Accessed on: 8th March 2020).

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy